US equities
|
SPCX
$175.09
▲+2.34%
NVDA
$242.47
▲+1.50%
MU
$1,069.65
▲+0.54%
MRVL
$291.56
▲+7.49%
AMD
$651.49
▲+3.12%
SNDK
$1,679.85
▼-1.43%
AVGO
$376.79
▲+3.94%
TSLA
$380.86
▲+0.56%
SPCX
$175.09
▲+2.34%
NVDA
$242.47
▲+1.50%
MU
$1,069.65
▲+0.54%
MRVL
$291.56
▲+7.49%
AMD
$651.49
▲+3.12%
SNDK
$1,679.85
▼-1.43%
AVGO
$376.79
▲+3.94%
TSLA
$380.86
▲+0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Gilead Sciences
(NQ:
GILD
)
142.87
-1.76 (-1.22%)
Delayed Quote
Updated: 10:53 AM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
...
29
30
31
32
33
34
35
36
37
...
78
79
Next >
Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects
↗
June 17, 2024
Gilead's recent data from two Phase 3 trials show higher adverse events and lower transplant rates in patients treated with magrolimab.
Via
Benzinga
Topics
Death
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
↗
June 14, 2024
The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug.
Via
Investor's Business Daily
What 8 Analyst Ratings Have To Say About Gilead Sciences
↗
June 14, 2024
Via
Benzinga
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
June 14, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
↗
June 13, 2024
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
↗
June 05, 2024
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
↗
May 21, 2024
Via
Benzinga
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
↗
June 08, 2024
These stocks offer great dividends and more.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
↗
June 07, 2024
Via
Benzinga
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
June 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Should You Buy the 3 Highest-Yielding Dividend Stocks in the Nasdaq-100?
↗
June 05, 2024
If you're looking for big income from blue-chip companies, these picks are for you.
Via
The Motley Fool
The Dividend Dynamos: 7 Stocks That Will Energize Your Income Stream
↗
June 05, 2024
Looking for some safe higher-yielding dividend stocks today? These are seven of the best options in this volatile market.
Via
InvestorPlace
7 Dividend Stocks to Invest In for a Lifetime of Income
↗
June 05, 2024
Discover top dividend stocks to buy for 2024 to maximize profits and minimize risks in today’s investing environment.
Via
InvestorPlace
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
June 05, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention Injection
↗
June 04, 2024
The US National Institutes of Health has launched two clinical trials to test a new long-acting form of HIV PrEP in cisgender women and people who inject drugs. These mid-stage studies will evaluate...
Via
Benzinga
3 Dividend Stocks That Even Ken Griffin Is Buying
↗
June 04, 2024
Billionaire investor Ken Griffin is filling the portfolio of his Citadel Advisors hedge fund with dividend paying stocks.
Via
InvestorPlace
Large Cap BIopharmaceuticals Overview
↗
June 03, 2024
As a defensive play healthcare is weighted at about 12% of the S&P 500.
Via
Talk Markets
Topics
Stocks
After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies
↗
June 03, 2024
Gilead Sciences and Arcus Biosciences report sustained efficacy and safety in the Phase 2 EDGE-Gastric study for upper GI cancers, showing improved progression-free survival and objective response...
Via
Benzinga
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
June 03, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
June 03, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
June 02, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
June 01, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead's Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder Cancer
↗
May 31, 2024
Gilead Sciences' announced topline results from the Phase 3 TROPiCS-04 study on Trodelvy for metastatic urothelial cancer. The study did not meet the primary endpoint of overall survival but showed...
Via
Benzinga
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
May 31, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Provides Update on Phase 3 TROPiCS-04 Study
May 30, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Is Nvidia Worth 35x Times Sales, History Says No
↗
May 29, 2024
You wouldn’t be able to tell just by looking at the S&P 500 daily change of +0.02%, but Tuesday was a pretty negative day, with the S&P 500 equal weight RSP ETF finishing down by almost 70 bps.
Via
Talk Markets
Topics
ETFs
Stocks
2 Beaten-Down Dividend Stocks to Buy and Hold For 10 Years
↗
May 28, 2024
These companies have grown their dividends despite some troubles.
Via
The Motley Fool
7 Biotech Stocks to Put on Your Breakthrough Radar
↗
May 27, 2024
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance.
Via
InvestorPlace
3 Biotech Stocks to Buy Now: May 2024
↗
May 22, 2024
As the biotech industry continues to rise in market prominence, investors should start considering what the best biotech stocks to buy are.
Via
InvestorPlace
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
May 22, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
< Previous
1
2
...
29
30
31
32
33
34
35
36
37
...
78
79
Next >
